Abstract
Meeting abstracts Glioma tumor lysate-pulsed dendritic cell (DC) vaccination is an effective treatment modality. However, cure rates in the established tumor setting are not therapeutically significant in our preclinical models. We inferred that immunosuppressive antigen presenting cells (iAPCs)
Highlights
Glioma tumor lysate-pulsed dendritic cell (DC) vaccination is an effective treatment modality
We inferred that immunosuppressive antigen presenting cells present in the tumor environment acting via the PD-1/ PD-L1 mechanism mediated immune suppression in malignant glioma
To test this hypothesis in our in vivo preclinical model, mice intracranially implanted with GL261 gliomas were treated with DC vaccination +/- murine anti-PD-1 mAb (RMP1-14, Bioxcell) blockade or a CNS-penetrant small molecule inhibitor of CSF-1R (PLX3397, Plexxikon) and overall survival was quantified
Summary
Glioma tumor lysate-pulsed dendritic cell (DC) vaccination is an effective treatment modality. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response Joseph Antonios*, Horacio Soto, Joey Orpilla, Namjo Shin, Richard Everson, Linda Liau, Robert Prins
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
